Tag Archive for: Infectious disease

ebola outbreak africa
Infectious disease

Berlin-developed Ebola vaccine heads toward African trial

The Coalition for Epidemic Preparedness Innovations (CEPI) is providing Egyptian biopharmaceutical company Minapharm with up to $16.5 million (€14 million) to advance another vaccine candidate against Bundibugyo Ebola virus into clinical development. The candidate was developed by Minapharm’s Berlin-based subsidiary ProBioGen using its proprietary MVA-CR19 platform. A Phase I trial is planned in Africa, with the broader aim of helping the continent build the capacity to respond rapidly to emerging outbreaks.

Read more
liver hepatitis B
GSK

GSK reports 19% functional cure rate for near-approval hepatitis B drug

GSK has linked its chronic hepatitis B drug candidate to a 19% functional cure rate across a pair of Phase III trials, clearing the bar it set for clinical relevance.

Read more
A scanning electron microscopic (SEM) image shows a strain of Staphylococcus aureus bacteria, the focus of LimmaTech AG from Switzerland, now being acquired by Eli LillyCDC/Janice Haney Carr
Eli Lilly

Three in One Go: LimmaTech, Curevo, Vaccine Company

Shopping spree at Eli Lilly? The US pharma giant is acquiring no fewer than three companies, all active in infectious diseases. Among them is Swiss biotech LimmaTech Biologics AG, led by former CureVac CEO Franz-Werner Haas. Yet Lilly’s ambitions extend well beyond classical infectious disease markets, targeting areas ranging from autoimmune disorders and antimicrobial resistance to chronic immune dysfunction and even cancer.

Read more
Lungen-Image by David_SMC from PixabayDavid_SMC from Pixabay
Infectious disease

Synairgen raises £18m for Phase 2 INVENT trial of SNG001

Synairgen plc (SNG) has announced the successful completion of a £18m funding round, primarily supported by TFG Asset Management. The funding will advance the Phase 2 INVENT trial, assessing SNG001, an inhaled formulation of the antiviral protein interferon beta, in mechanically ventilated patients with severe viral lung infections.

Read more